Inotek Pharmaceuticals to Present at the BIO CEO and Investor Conference

LEXINGTON, Mass.--()--Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that David P. Southwell, President and Chief Executive Officer of Inotek, will present at the BIO CEO and Investor Conference on Tuesday, February 14, 2017 at 1:00pm EST at the Waldorf Astoria Hotel in New York City.

About Inotek Pharmaceuticals Corporation
Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development. Trabodenoson was developed in Inotek’s laboratories and is designed to restore the eye’s natural pressure control mechanism. Additionally, the Company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. For more information, please visit www.inotekpharma.com. The inclusion of our website address here and elsewhere in this press release does not include or incorporate by reference the information on our website into this press release.

Forward-Looking Statements
This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek," "will," "may" or similar expressions. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Inotek Contact:
Claudine Prowse, PhD, 781-552-4305
Vice President, Strategy and IRO
IR@inotekpharma.com

Release Summary

Inotek announces presentation at the BIO CEO and Investor Conference.

Contacts

Inotek Contact:
Claudine Prowse, PhD, 781-552-4305
Vice President, Strategy and IRO
IR@inotekpharma.com